A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

August 25, 2023

Study Completion Date

June 4, 2024

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

TQ-A3334 tablets

TQ-A3334 is a highly efficient and highly selective Toll-like receptor-7 (TLR-7) agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including interferon alpha (IFN-α), Interleukin 12 (IL-12), Tumor Necrosis Factor Alpha (TNF-α), and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.

DRUG

TQ-A3334 tablets + Anlotinib capsules

"TQ-A3334 is a highly efficient and highly selective TLR-7 agonist. TLR-7 can induce the release of a series of pro-inflammatory cytokines, including IFN-α (interferon-α), IL-12 (Interleukin 12), TNF-α, and promote the maturation and antigen presentation of dendritic cells, play an antitumor effect.~Anlotinib hydrochloride is a muti-target tyrosine kinase inhibitor."

Trial Locations (1)

210023

Jingling Hospital, Nanjing

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY